NCT05585983View on ClinicalTrials.gov

INfluenza VaccInation To Mitigate typE 1 Diabetes

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 14, 2022

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2027

Conditions
Diabetes Mellitus, Type 1
Interventions
BIOLOGICAL

Vaxigrip Tetra Sanofi Pasteur Europe

We will use 0.5 mL standard dose quadrivalent influenza vaccine containing 15 μg of hemagglutinin per strain consistent with WHO recommendations according to season.

Trial Locations (10)

Unknown

RECRUITING

Aalborg University Hospital, Aalborg

RECRUITING

Aarhus University Hospital, Aarhus

RECRUITING

Steno Diabetes Center Copenhagen, Copenhagen

RECRUITING

Gødstrup Hospital, Herning

RECRUITING

Holbaek Sygehus, Holbæk

RECRUITING

Nykoebing F Sygehus, Nykøbing Falster

RECRUITING

Randers Regional Hospital, Randers

RECRUITING

Sjællands Universitetssygehus, Roskilde

RECRUITING

Slagelse Hospital, Slagelse

RECRUITING

Viborg Regional Hospital, Viborg

All Listed Sponsors
lead

Aarhus University Hospital

OTHER